Physician profile
Rudolph Willis
NPI 1104887819
$4,692.31
in general payments reported to CMS, 2019-2025
18 companies · $405 in 2025
The $405 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $444 · 2021: $416 · 2022: $1,013 · 2023: $1,236 · 2024: $654 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,204.25 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $884.98 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $503.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $502.07 | 2020-2023 | |
| Kowa Pharmaceuticals America, INC. | $378.36 | 2022-2023 | Seglentis, Livalo |
| Merck Sharp & Dohme LLC | $346.70 | 2019-2022 | |
| Mannkind Corporation | $142.84 | 2023-2024 | Afrezza |
| Glaxosmithkline, LLC. | $139.20 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.30 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.04 | 2019-2025 | Jardiance |
| Orexo US, INC. | $93.27 | 2024-2025 | Zubsolv |
| Janssen Pharmaceuticals, INC | $74.82 | 2020 | |
| Indivior INC. | $51.50 | 2025 | Sublocade |
| Exact Sciences Corporation | $44.47 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $31.23 | 2025 | Repatha |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.32 | 2023 | |
| Gilead Sciences, INC. | $14.61 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rudolph Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.